Previous close | 0.2700 |
Open | 0.3100 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 120.00 |
Expiry date | 2024-07-19 |
Day's range | 0.1900 - 0.4400 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems – Lingo™ and Libre Rio™, which are based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology1, now used by about 6 million people globally2. The newly cleared systems have been intentionally designed to meet different needs – Lingo for consumers who want to better understand and improve their health and welln
We recently compiled the list of 25 Best Dividend Aristocrats Stocks According to Analysts. Since Abbott Laboratories (NYSE:ABT) ranks higher on our list, we have analyzed the stock in detail. The age-old debate of investing in dividend growth or high-yield stocks continues to reappear within the dividend investing realm. Between these two, dividend growth is currently […]
The average brokerage recommendation (ABR) for Abbott (ABT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?